Novavax (NVAX) Tops Q1 EPS by 18c; offers guidance
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $10.63 +0.28%
Financial Fact:
Basic and diluted net loss per share: -0.24
Today's EPS Names:
OCCI, IPX, ALZN, More
Financial Fact:
Basic and diluted net loss per share: -0.24
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q1 EPS of ($0.06), $0.18 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $139.51 million versus the consensus estimate of $79.31 million.
GUIDANCE:
Novavax sees FY2026 revenue of $230-270 million, versus the consensus of $394.3 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
- ShinyHunters hackers say they stole psychiatric and medical records of DBI staff - Reuters
- NeuroSense posts narrower H1 loss, targets Canada drug filing by December
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
